Pfizer shares fall despite upbeat 2018 guidance and market beating fourth quarter numbers
Pfizer expects a "meaningfully lower" effective tax rate this year and a repatriation tax liability of about US$15bn over eight years
Company
Pfizer Inc
NYSE:PFE
Pfizer Inc is a research-based biopharmaceutical company. The company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1.
293 stories · page 3 of 3
Hardware & electrical equipment
Apple, Nvidia, Kohl's Corp and Pfizer - PRE-MARKET
Proactive takes a look at the pre-market deals in New York on Monday to see what's attracting interest
Darden Restaurants, Pfizer, Carnival Corp, Heico, Campbell Soup - PRE-MARKET
A look at some of the early movers in New York pre-market trade
Strong pneumonia vaccine sales help Pfizer to top Street estimates
Excluding one-off items, Pfizer earned US$0.67 a share, beating the average analyst estimate of US$0.64 per share
Geron Corporation, Pfizer, Under Armour and more - PRE-MARKET
Proactive keeps and eye on the share needle before the bell in New York
PreveCeutical Medical appoints chief scientific officer to board of directors
“[Dr Makarand Jawadekar’s] exceptional knowledge in drug delivery technologies and experience in the pharmaceutical industry will be of tremendous benefit to the company”
Archive
Lloyds Banking looking to put its trials behind it
PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
Lloyds, Barclays and RBS under the microscope with release of third quarter earnings
The week ahead includes third quarter earnings from Lloyds, Barclays and RBS along with trading updates from Shire, IAG and GSK
US benchmarks head higher as Catalonia, Apple and Spielberg in the frame
US benchmarks were sliding towards a positive close on Tuesday
Pfizer ponders spinning off its Consumer Healthcare division
The viagra maker is considering whether it can release value by spinning off some or all of its consumer healthcare business, which includes brands such as Advil, Chapstick and Preparation H.
Pfizer, Amgen , Clovis Oncology and more - PRE-MARKET
A look at what stocks are moving the needle, up and down, before the bell in New York
Versartis shares take a dive after growth hormone deficiency treatment trial fails primary endpoint
Chief executive Jay Shepard said the company will be issuing a corporate update later this year
FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths
US, Food and Drug Administration, Pfizer Inc, Mylan, EpiPen, anaphylactic shock, warning letter, Meridian Medical Technologies, pharma, drugs
Pfizer receives FDA approval for acute myeloid leukemia therapy
The treatment also approved for children, two years and older with relapsed or refractory CD33-positive acute myeloid leukemia.
Pfizer quarterly revenue falls more than forecast on lower demand for Prevnar and Enbrel
Pfizer has raised its earnings guidance and expects up to 30 approvals for its pipeline of medicines over the next five years
FTSE 100 closes 51 up with engineer Rolls Royce in the driving seat
With an hour and a quarter of trading to go, the UK benchmark index was ahead 58 points at 7,430, just easing back from the afternoon peak of 7,438.90
Pfizer cuts losses on Brazil drug maker with sale for nominal sum
Generic drug makers in the country have struggled due to rising raw material costs and a prolonged recession.
Eli Lilly /Pfizer back pain treatment gets fast track status from US Food and Drug Administration
A phase III trial is currently underway and includes six studies in 7,000 patients suffering osteoarthritis, chronic low back pain and cancer.
GlaxoSmithKline makes submissions for key HIV single-tablet treatment to both the EMA and the US FDA
The submission is for a combination of dolutegravir, developed by ViiV Healthcare and Tivicay, and rilpivirine, developed by Edurant, and Janssen Sciences Ireland UC
US stocks close higher as oil price firms
President Trump and the OPEC meeting on Thursday are sure to be big themes this week
Galileo Resources soars higher as initial drilling at Concordia copper project completed
A look at some of the biggest London-listed risers and fallers today
FTSE 100 dragged lower as Brexit worries whirl; Sainsbury's weighs
The FTSE 100 closed 15.52 down at 7,234 with Sainsbury's and mining shares under pressure
US shares end higher as Fed in focus; US crude tanks
Wall Street shares finished higher as markets look to the Fed meeting and another host of earnings
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
Allergan to buy LifeCell for $2.9bn cash
Allergan, the maker of wrinkle-filler Botox, said on Tuesday that it has agreed to buy regenerative medicine company LifeCell for $2.9bn in cash
GlaxoSmithKline’s fast-growing HIV drug business gets another boost
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
Archive
Trending - fines, HSBC, JP Morgan, Pfizer and bird flu
A look at some of the big, trending topics on Wednesday
Trending: Which 80 small- mid- and large-cap stocks will do well over four years?
Watching the way Wall Street index tickers have raced to fresh record highs on both Monday and Tuesday, investors might be forgiven for thinking that pretty much any stock is doing well on the so-called “Trump Trade”, coined in the wake of
US stocks end mixed as winners and losers assess Trump
US stocks seesawed through Thursday, with the Dow hitting a record high intraday and close, as banks and pharma stocks lapped up the perceived benefits of President-elect Donald Trump’s victory, while tech stocks sank on worries about his f
US small-caps among the top risers after Trump victory
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
Pfizer trims 2016 profit forecast as it scraps cholesterol drug
The US drug maker has knocked five cents off of its per share earnings forecast for this year
Pfizer’s spoiler on Johnson & Johnson’s earnings rally
The world’s largest healthcare company Johnson & Johnson’s third-quarter earnings per share came in 3 cents higher than analysts’ forecasts. But Pfizer said it will launch a cheaper competing product to J&J's flagship drug Remicade
US stocks gain in healthy sector rally
US stocks ended higher on Tuesday with a boost from high drama in the healthcare sector
Pharmas Regeneron and Teva shares hit by FDA order
Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Archive
Pfizer, Etsy and eBay on brokers’ radars
Pfizer bruised by a downgrade from Jefferies but Wedbush assume coverage of eCommerce names eBay and Etsy
AstraZeneca up after diabetes combo passes phase III
The trial met the met the primary endpoint of a better performance that the single medicines alone said the pharma
Merck/Pfizer ready new diabetes drug after trial success
Ertugliflozin is an investigational oral treatment for type 2 diabetes
AstraZeneca to sell antibiotics business to Pfizer
The deal is for its late-stage small molecule antibiotics business and involves three already-approved antibiotics - Merrem, Zinforo and Zavicefta - and two drugs in clinical trials (ATM-AVI and CXL).
Pfizer wins battle for Medivation with US$14bn offer
Medivation has been on the block since April when French group Sanofi offered US$52.50 per share.
Pfizer close to buying Medivation, ChemChina gets US nod for Syngenta deal
Pfizer's takeover talks with Medivation are at an advanced stage, so say the Financial Times, Wall Street Journal and Bloomberg.
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
Radius Health shares rise 10% on continued bid rumours
Radius Health Inc shares were 10% higher on Friday on continued bid rumours
Trending: Brexit seen as a lever to more transatlantic M&A
When Brexit was first mooted by the Leave camp over a year ago, the slogan was all about taking back control of sovereignty and executive powers from the European Union. No one ever saw it as a conduit for taking control of US companies, di
Medivation rejects latest Sanofi bid
Medivation officially rejects the latest acquisition bid of US$58 per share from Sanofi.
Pharma Pfizer unfazed after Jefferies trims price target
Pharmaceuticals behemoth Pfizer Inc shares remained resilient after broker Jefferies trimmed its price target on the pharmaceutical giant's stock to $42 from $40, as Pfizer leadership prepares to decide whether to separate its global establ
Pfizer treatment passes second efficacy trial for psoriatic arthritis
The disease is normally associated with people suffering from psoriasis
US stocks receive lift from M&A activity in pharma sector
Merger activity and a resurgent oil price have lit a fire under US equities
Pharma M&A activity provides some juice for US stocks
Merger activity and a resurgent oil price have lit a fire under US equities
Trending: Macys, Staples and the worst Wall Street M&A year on record
If the oil and commodities sectors have had a rough ride this year, traders' shun words on Wednesday on Wall Street were Macys, Staples, and retail as US faces up to worst M&A deal failures on record
Allergan shares rise after $10bn buyback plan
Allergan shares rise after the company says it will buy back up to $10bn in stock following a swing to a first-quarter profit on a surge in sales of key drugs, including the wrinkle and muscle spasm treatment Botox
Archive
Pfizer a buy at lower levels, says Jefferies
Pfizer, one of the world's biggest pharmaceutical companies, may well be licking its wounds after the collapse of its planned merger with Allergan this week, but brokers at Jefferies reiterate a Buy on the stock
Archive
Brokers: Chip giants in focus
Graphics chip maker Nvidia's analyst day was well-attended. Meanwhile, RBC is perturbed at the number of top executives leaving Intel.
US investors sit on their hands ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Wall Street shares push higher after shock US oil inventories drop, Fed sidelined
US small-cap stocks swing higher after a surprise drop in US weekly oil inventories boosts energy futures and calm jitters over minutes of the Federal Reserve's recent rate-setting meeting
US investors sit on their hands ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Stocks tread water ahead of Fed minutes
Neither Pfizer or Allergan showed any ill effects from the collapse of the proposed merger
Stocks set for strong start ahead of release of FOMC minutes
Pfizer is likely to be in focus after it called off its proposed acquisition of Allergan
Trending: Pfizer tie up with Allergan catches a cold
Not for the first time has the ambitious and acquisitive pharmaceutical behemoth Pfizer has been upset at the merger altar, but with its Allergan deal under threat, the company may well step back and assess shareholder value
Archive
Papers: Pfizer Inc-Allergan deal in doubt after tax changes
Also mentioned: Tesla, Walt Disney, Yahoo and Twitter
Archive
Trending - Data transfer pact, big oil and low crude prices
Away from the chatter of the Iowa election, big cap global oilers are in focus today with some of the biggest names reporting as the turmoil in crude markets continues unabated.....
Pfizer tops Q4 hopes but lowers guidance for 2016
Revenue rose to US$14.05bn from US$13.1bn, also ahead of expectations of around US$13.6bn.
e-Therapeutics hires life sciences veteran as chairman
Professor Malcolm Young is stepping down as chairman but will remain in his role as chief executive.
Pfizer agrees US$150bn Allergan merger
The combined group will become the world’s largest drug company.
Pfizer's Allergan bid in spotlight, Wall Street trades lower
All of the three benchmark indexes are in negative territory.
M&A activity pushes back towards pre-crash highs
Deals on Monday took this year's M&A total above 2014
Potential merger of Allergan and Pfizer sparks tax debate
Irish based botox maker Allergan and US drugs giant Pfizer confirmed they are in merger talks.
Archive
Wall Street drops amid downbeat GDP data
The preliminary gross domestic product (GDP) number came in a bit weaker than expected.
Stocks trim losses after soft GDP data
A half-hearted rally was under way in the lunchtime trading session,
U.S. Risers/Fallers: Allergan, Pfizer, Time Warner Cable, PayPal, GoPro, Yelp, MasterCard, Aetna
Below are the main news driven share price changes at 12:04 p.m. in New York on Thursday:
Allergan, Pfizer confirm preliminary merger talks
A potential merger would create the world’s largest drug maker.
US stocks slide as GDP numbers muddy the Fed's waters
There is much to think about this morning with the prospect of a 2015 rate hike back on the table and GDP a bit weaker than expected
US stocks to step back after Fed hints of December rate rise
The Fed went off-piste as far as the market was concerned with its comments yesterday following the interest rate decision
Archive
Wall Street trading lower on falling oil, ahead of Fed meeting
All three of the major benchmarks are in the red ahead of the closing of trading.
Oil stocks lead downward drift
The morning session was a lethargic one despite being choc-full of trading updates
U.S. Risers/Fallers: Pfizer, Alibaba, JetBlue, Coach, DuPont, Comcast, UPS, Marvell, Ford
Below are the main news driven share price changes at 12:03 p.m. in New York on Tuesday:
Investments and investor services
US stocks drift lower, with all eyes on the Fed
Oil stocks are on the slide as the price of crude continues to fall
Pfizer tops Q3 profit estimates, lifts 2015 outlook
The U.S. drugmaker benefited from demand for its pneumonia vaccine and breast cancer drug.
Investors expected to lie low ahead of Fed meeting
Following the lead of European markets, US stocks are set to open slightly lower
Archive
Wall Street retreats as oil slump weighs
Valeant extends losses; Piedmont Natural Gas surges 38%
Wall Street opens lower ahead of earnings reports, Fed meeting
Valeant extends losses; Piedmont Natural Gas surges 38%
Pfizer's drug patent deemed invalid by UK High Court
Pfizer's drug Lyrica was originally developed for epilepsy.
Wall Street breaks 5-day losing run as investors look for tomorrow’s Fed statement
U.S. stocks halted the five-day losing streak today, as investors looked past softer economic reports and a continued rout in China’s stock market, and waited for the outcome of the two-day Federal Reserve. The S&P 500 (INDEXSP:.I
Wall Street on track to end 5-day rout as China selloff stalls
Wall Street is poised to end a five-session losing streak, amid better-than-forecast earnings, as Chinese equities pulled back from a selloff, and ahead of a highly anticipated Federal Reserve meeting. Futures for the Dow Jones Industrial A
Wall Street trades higher on hopes Greece will reach deal with lenders to avert default
Wall Street climbed today on hopes Greece and its lenders will reach a deal to avert a default. The S&P 500 (INDEXSP:.INX) rose 0.7 percent to 2,124.55 at 3:12 p.m. in New York. The 30-company Dow Jones Industrial Average (INDEXDJX:.DJI
Wall Street trades lower amid Greek debt talks stalemate
Wall Street traded lower today amid mounting worries Greece won’t strike a debt deal with its creditors in time to avoid default. The S&P 500 (INDEXSP:.INX) fell 0.7 percent to 2,094.47 at 3:45 a.m. in Toronto. The 30-company Dow